According to Cognitive Market Research, the global Anaphylaxis Treatment market size is USD 2841.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 9.00% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 1136.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 852.36 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 653.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.0% from 2024 to 2031.
Latin America had a market share for more than 5% of the global revenue with a market size of USD 142.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 56.82 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031.
The Epinephrine held the highest Anaphylaxis Treatment market revenue share in 2024.
